Financial Data and Key Metrics Changes - The company reported half a million in revenue from the first month of the product launch, which is considered encouraging for a new product [13] - The cash position as of March 31 was reported to be between 113 million and 119 million, with a reduced cash burn rate extending the cash runway by up to 50 million, allowing the company to expect to get through the end of 2026 [38][39] Business Line Data and Key Metrics Changes - The company is tracking sales and intermediary metrics, with active files submitted to value analysis committees in over 40 trauma centers, which corresponds to nearly a quarter of the 200 level one trauma centers in the US [15] - The company anticipates that the substantial bulk of sales will occur in the second half of the year due to the lengthy value analysis committee process [19] Market Data and Key Metrics Changes - There are approximately 26,000 cases of vascular injury requiring surgery annually in the US, concentrated in about 200 level one trauma centers, indicating a finite number of call points for the company's sales efforts [7][8] - The company has developed a budget impact model showing that the cost of caring for patients treated with SIMVEST is lower than that for patients treated with synthetic grafts, which could drive adoption [20][21] Company Strategy and Development Direction - The company is focusing on expanding its product offerings, including evaluating engineered blood vessels for fistula repair in end-stage renal patients and has embarked on a phase three trial for this indication [23][25] - The company plans to file a supplemental BLA for the dialysis indication in the second half of 2026, contingent on positive interim analysis results from the ongoing trial [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch, noting that while the initial uptake may be slow, they expect significant results as the process matures [18] - The company has not provided specific revenue guidance for the first year due to the lengthy value analysis committee process but indicated a consensus estimate of around 7 to 8 million for the year [37] Other Important Information - The company has completed three phase two trials for peripheral arterial disease, showing outstanding limb salvage rates, and is in the process of designing a phase three program [31][35] - Long-term military results and civilian clinical data are expected to be published soon, indicating a strong pipeline of news flow [30] Q&A Session Summary Question: What is the company's current cash position and expected cash runway? - The company reported a cash position of between 113 million and 119 million as of March 31 and expects to extend its cash runway through the end of 2026 due to a reduced cash burn rate [38][39] Question: What metrics are being tracked to ensure the success of SymVest in the market? - The company is tracking sales and intermediary metrics, including submissions to value analysis committees in trauma centers, which are crucial for hospital adoption [15] Question: What are the next steps in the company's clinical programs? - The company plans to publish results from the phase three trial for dialysis access and expects to file a supplemental BLA in the second half of 2026 if interim results are positive [28]

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq in New York, NY on Tuesday, May 20, 2025. Management will also be available for one-on-one meetings. Event: H.C. ...

Financial Performance - Total revenue for Q1 2025 was $517,000, compared to $0 in Q1 2024, with product revenue of $147,000 and contract revenue of $370,000[17]. - The net income for Q1 2025 was $39.1 million, a significant improvement from a net loss of $31.9 million in Q1 2024[17]. - For the three months ended March 31, 2025, the net income attributable to common stockholders was $36,765,000, compared to a net loss of $31,896,000 for the same period in 2024, representing a significant turnaround[61]. - Basic and diluted net income per share attributable to common stockholders for Q1 2025 was $0.28, compared to a loss of $0.29 per share in Q1 2024[61]. - The company incurred operating losses of approximately $23.2 million for the three months ended March 31, 2025, compared to $26.6 million for the same period in 2024[214]. Cash and Liquidity - Cash and cash equivalents increased to $62.8 million as of March 31, 2025, up from $44.9 million at the end of 2024[16]. - The accumulated deficit decreased to $646.9 million as of March 31, 2025, from $686.0 million at the end of 2024[26]. - The company raised $47 million from a public offering in Q1 2025, contributing to a net increase in cash and cash equivalents[22]. - As of March 31, 2025, the company had available cash and cash equivalents of $62.8 million, with an additional $72.6 million remaining under the ATM Facility[31][32]. - Total cash, cash equivalents, and restricted cash amounted to $113.2 million as of March 31, 2025, up from $95.3 million as of December 31, 2024[58]. Operating Expenses and R&D - Operating expenses decreased to $23.7 million in Q1 2025 from $26.6 million in Q1 2024, primarily due to a reduction in research and development costs[17]. - Total research and development expenses for the three months ended March 31, 2025, were $15.4 million, a decrease of 27.0% compared to $21.3 million for the same period in 2024[44]. - The company implemented a cost reduction action to reduce its workforce by approximately 31 employees to improve cash runway[32]. Assets and Liabilities - The total assets increased to $162.6 million as of March 31, 2025, compared to $137.9 million at the end of 2024[16]. - The company recorded a revenue interest liability related to the Purchase Agreement, net of a debt discount totaling $4.6 million, reflecting the contractual repayment obligation based on future revenue estimates[99]. - As of March 31, 2025, the revenue interest liability was $66.4 million, up from $64.2 million as of December 31, 2024, reflecting an increase of approximately 3.4%[100]. Strategic Partnerships and Agreements - The company has a strategic partnership with Fresenius Medical Care to distribute its 6 millimeter ATEV for specific indications outside the United States, which is crucial for market expansion[65]. - The distribution agreement with Fresenius Medical Care includes a $150 million financing transaction and a $25 million investment as part of a private placement offering[192]. - The Company entered into a JDRF Agreement on April 1, 2023, with funding up to $0.8 million based on achieving specific R&D milestones related to the BVP product candidate[179]. Regulatory and Product Development - The FDA granted full approval for the ATEV under the brand name Symvess on December 19, 2024, for use in adults as a vascular conduit for extremity arterial injury[210]. - The company commenced commercial shipments of Symvess in March 2025 following FDA authorization[212]. - The company plans to submit a supplemental BLA for the ATEV for AV access for hemodialysis in the second half of 2026, depending on interim results from the ongoing V012 Phase 3 trial[213]. Stock and Equity - The weighted-average common shares outstanding increased to 131,496,877 in Q1 2025 from 108,246,008 in Q1 2024, indicating a 21.5% increase in shares[61]. - The Company has $47.5 million remaining available for sales of Common Stock under the Common Stock Purchase Agreement as of March 31, 2025[110]. - The Company sold 500,000 shares to Lincoln Park for aggregate gross proceeds of $2.5 million through the Common Stock Purchase Agreement[110]. Risks and Future Outlook - The company expects to continue incurring substantial operating losses and negative cash flows as it advances its product candidates[26]. - The company believes it has the ability to fund operations at least into the second half of 2026 based on current cash and management plans[32]. - The company is subject to various risks, including successful commercialization of its product candidates and the ability to secure additional capital for operations[63].

Company Performance - Humacyte, Inc. reported a quarterly loss of $0.10 per share, better than the Zacks Consensus Estimate of a loss of $0.19, and an improvement from a loss of $0.29 per share a year ago, representing an earnings surprise of 47.37% [1] - The company posted revenues of $0.52 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.45%, compared to zero revenues a year ago [2] - Humacyte's shares have declined approximately 73.9% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $1.05 million, and for the current fiscal year, it is -$0.69 on revenues of $9.66 million [7] - The estimate revisions trend for Humacyte is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expectations of outperforming the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Humacyte belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - The company reported revenue of $517,000 for Q1 2025, with $147,000 from the U.S. commercial launch of CymVest and $370,000 from a research collaboration, compared to no revenue in Q1 2024 [18] - Net income for Q1 2025 was $39.1 million, a significant increase from a net loss of $31.9 million in Q1 2024, primarily due to a non-cash remeasurement of a contingent earn-out liability [20] - Cash, cash equivalents, and restricted cash totaled $113.2 million as of March 31, 2025, with net cash provided of $17.9 million for the first three months of 2025, down from $35.1 million in the same period of 2024 [21] Business Line Data and Key Metrics Changes - The commercial launch of CymVest began in late February 2025, with initial shipments to three level one trauma centers and 45 hospitals evaluating the product [7][9] - Five hospitals have approved the purchase of CymVest, with expectations for further approvals in the second quarter [8] - Research and development expenses decreased to $15.4 million in Q1 2025 from $21.3 million in Q1 2024, attributed to reduced material costs and clinical study costs [19] Market Data and Key Metrics Changes - The company is focusing on both civilian and military markets for CymVest, with interest expressed by multiple military treatment facilities [9] - The VAC process has shown a good conversion rate for approvals, although some delays were noted due to external factors such as media coverage [30][34] Company Strategy and Development Direction - The primary focus is on the commercial launch of CymVest and expanding the bioengineering pipeline, with plans to file an IND for a small diameter ATEF for coronary artery bypass grafting later in 2025 [4][5] - The company aims to submit a supplemental BLA for the ATEF in dialysis access in 2026, leveraging positive results from ongoing clinical trials [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial execution and the potential of the pipeline programs, despite a volatile economic environment [4][23] - The company is addressing unfounded criticisms regarding CymVest with scientific data and is optimistic about the long-term outcomes of clinical trials [6] Other Important Information - The company implemented workforce reductions to extend cash runway and align organizational structure with business objectives, estimating net savings of approximately $13.8 million in 2025 [16][17] - The publication of a budget impact model in March 2025 supports the economic value of CymVest, which is expected to aid in gaining traction in the market [8] Q&A Session Summary Question: Can you provide insights on the experience of the three sites that purchased CymVest? - The company has performed its first implant at one site with a sales representative present, but many surgeons are experienced enough to proceed without direct support [29][30] Question: How is the uptake of CymVest expected to progress this year? - The company anticipates a strong conversion rate from VAC approvals, with most sales expected in the second half of the year [34][44] Question: What is the process for military hospitals to order CymVest once on ECAT? - Military hospitals can order CymVest through ECAT, but surgeon champions are essential for successful procurement [35][36] Question: Are current revenue estimates for 2025 still reasonable? - Management remains comfortable with the revenue guidance provided earlier, expecting most revenues to come in the second half of the year [44] Question: What learnings from previous Phase III studies are being applied to the VO12 trial? - The company is focusing on the handling of the conduit in dialysis centers and adherence to clinical trial protocols to ensure positive outcomes [48] Question: What is the status of the partnership with Fresenius? - The partnership remains strong, with ongoing efforts to quantify the costs associated with ineffective access in patients, aligning with Fresenius's business objectives [51]

Financial Performance - Total revenues for Q1 2025 were $517,000, with $147,000 from the initial U.S. commercial launch of Symvess and $370,000 from a research collaboration[11]. - Net income for Q1 2025 was $39.1 million, compared to a net loss of $31.9 million in Q1 2024, largely due to a non-cash remeasurement of the contingent earnout liability[11]. - Total revenue for Q1 2025 was $517,000, compared to $0 in Q1 2024, indicating a significant growth[27]. - Product revenue was $147,000, while contract revenue was $370,000, both contributing to the total revenue[27]. - Operating expenses decreased to $23,701,000 in Q1 2025 from $26,578,000 in Q1 2024, reflecting a reduction of approximately 11%[27]. - The net income for Q1 2025 was $39,139,000, a turnaround from a net loss of $31,896,000 in Q1 2024[27]. - Net income per share, basic, was $0.28 in Q1 2025, compared to a loss of $0.29 per share in Q1 2024[27]. Cash and Assets - As of March 31, 2025, Humacyte reported cash, cash equivalents, and restricted cash of $113.2 million[11]. - Cash and cash equivalents increased to $62,847,000 as of March 31, 2025, up from $44,937,000 at the end of 2023[29]. - Total assets rose to $162,553,000 as of March 31, 2025, compared to $137,872,000 at the end of 2023, marking an increase of approximately 18%[29]. - Total liabilities decreased significantly to $126,510,000 from $190,541,000, indicating a reduction of about 34%[29]. - Stockholders' equity improved to $36,043,000 as of March 31, 2025, compared to a deficit of $52,669,000 at the end of 2023[29]. Cost Management - The company implemented cost reduction measures, including a workforce reduction of approximately 31 employees, expected to save about $13.8 million in 2025 and up to $38.0 million in 2026[7]. - Research and development expenses for Q1 2025 were $15.4 million, down from $21.3 million in Q1 2024, primarily due to decreased materials costs[11]. Product Development and Market Approval - 45 hospitals have initiated the Value Analysis Committee (VAC) approval process for Symvess, with five hospitals already approving its purchase[4]. - A total of 84 patients have been enrolled in the V012 Phase 3 clinical trial for dialysis, with an interim analysis planned upon reaching the one-year follow-up for the first 80 patients[8]. - Humacyte plans to file an Investigational New Drug (IND) application with the FDA for first-in-human clinical testing of the small-diameter ATEV in coronary artery bypass grafting (CABG) later this year[8]. Economic Value - The economic value of Symvess is projected to be lower than that of synthetic grafts, with significant cost savings attributed to reduced amputation and infection rates[8]. - The company reported a change in fair value of contingent earnout liability of $49,731,000 in Q1 2025, compared to a loss of $4,593,000 in Q1 2024[27].

Core Insights - Humacyte, Inc. has successfully launched its product Symvess™ for treating extremity vascular trauma, marking a significant milestone for the company [2][3] - The company reported total revenues of $517,000 for the first quarter of 2025, with $147,000 from the initial commercial sales of Symvess and $370,000 from a research collaboration [9][27] - Humacyte completed a public offering that raised $46.7 million in net proceeds, which will help extend its cash runway [6][9] Market Launch and Sales - The commercial launch of Symvess began in late February 2025, with initial shipments to three Level 1 trauma centers [3] - 45 hospitals have initiated the Value Analysis Committee (VAC) approval process for Symvess, with five hospitals already approving its purchase [2][3] - The company anticipates further approvals and sales growth in the upcoming quarters [3] Financial Performance - The first quarter of 2025 saw a revenue increase to $517,000 compared to no revenue in the same period of 2024 [9][27] - Research and development expenses decreased to $15.4 million from $21.3 million year-over-year, attributed to reduced material costs and clinical study expenses [9][27] - General and administrative expenses rose to $8.1 million from $5.3 million, primarily due to the costs associated with the commercial launch of Symvess [9][27] Cost Management and Future Plans - The company implemented cost reduction measures, including workforce reductions and deferring new hires, aiming for estimated savings of approximately $13.8 million in 2025 and up to $38 million in 2026 [6][9] - Humacyte plans to file an Investigational New Drug (IND) application with the FDA for the small-diameter ATEV™ in coronary artery bypass grafting (CABG) later this year [2][8] - The company is on track to submit a supplemental Biologics License Application (BLA) for ATEV in dialysis in 2026, following a major enrollment milestone in its Phase 3 trial [2][8] Corporate Developments - Humacyte was issued a new U.S. patent in January 2025, providing protection for its biomanufacturing platform until 2040 [4] - The company reported a net income of $39.1 million for the first quarter of 2025, a significant improvement from a net loss of $31.9 million in the same period of 2024 [17][27] - As of March 31, 2025, Humacyte had cash, cash equivalents, and restricted cash totaling $113.2 million [17][28]

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to provide a corporate and financial update. Title:Humacyte First Quarter 2025 Financial Results and Corporate UpdateDate:May 13, 2025Ti ...

Company Performance - Humacyte, Inc. (HUMA) ended the latest trading session at $1.45, reflecting a +1.4% adjustment from the previous day's close, outperforming the S&P 500 which gained 0.15% [1] - The stock has decreased by 4.03% over the past month, which is worse than the Medical sector's loss of 4.39% and the S&P 500's loss of 0.21% [1] Earnings Forecast - Humacyte, Inc. is projected to report earnings of -$0.19 per share in the upcoming release, indicating a year-over-year growth of 34.48% [2] Analyst Revisions - Recent revisions to analyst forecasts for Humacyte, Inc. are important as they reflect changes in short-term business dynamics, with positive revisions indicating analysts' confidence in the company's performance [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Over the last 30 days, the Zacks Consensus EPS estimate for Humacyte, Inc. has increased by 14.6%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Industry Context - Humacyte, Inc. operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - Humacyte, Inc. (HUMA) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to significant stock price movements when estimates are revised [4]. Recent Performance and Projections - For the fiscal year ending December 2025, Humacyte, Inc. is expected to earn -$0.69 per share, reflecting a 34.3% change from the previous year's reported number [8]. - Over the past three months, the Zacks Consensus Estimate for Humacyte has increased by 16.9%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - Humacyte's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].